May 29, 2017
Bone Therapeutics welcomes new members of the Board
Bone Therapeutics has appointed Steve Swinson and Damian Marron to its Board of Directors as Non-Executive Directors.
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
May 29, 2017
FDA OK’s expanded use of Novartis’s cancer drug
The US Food and Drug Administration (FDA) approved the expanded use of Novartis’s Zykadia (ceritinib) to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test.
May 26, 2017
Drug approvals bounce back as R&D labs churn out new winners
The number of new drugs approved for sale in United States and Europe has bounced back this year, suggesting a marked slowdown in 2016 was an aberration rather than a sign of flagging research and development productivity.
May 25, 2017
Diplomat to sell Sanofi’s and Regeneron’s rheumatoid arthritis drug in U.S.
Diplomat Pharmacy will sell Sanofi’s and Regeneron Pharmaceuticals’s Kevzara (sarilumab), recently approved by the FDA to treat adults with moderately to severely active rheumatoid arthritis (RA) who have an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs).
May 25, 2017
FDA’s Advisory Committee recommends approval of Puma Biotechnology’s breast cancer drug
FDA’s Oncologic Drugs Advisory Committee (ODAC) has recommended approval of Puma Biotechnology’s PB272 (neratinib) for the extended adjuvant treatment of HER2-positive early stage breast cancer based on finding that the risk-benefit profile of neratinib is favorable.
May 25, 2017
Arix Bioscience co-leads $45 million Series B investment round for Harpoon Therapeutics
Harpoon Therapeutics, a new Arix Group Business, has closed a Series B investment round raising $45 million.
May 25, 2017
FDA OK’s Roche’s arteritis drug
The U.S. Food and Drug Administration (FDA) has approved Roche’s Actemra/RoActemra (tocilizumab) subcutaneous injection for the treatment of GCA, a chronic and severe autoimmune condition.
May 25, 2017
Therapix Biosciences looks for new CEO
Therapix Biosciences, a specialty clinical stage pharmaceutical company specializing in the development of cannabinoid-based drugs, has announced that the company’s Chief Executive Officer Dr. Elran Haber will step down from his position to pursue other professional opportunities.
May 24, 2017
FDA Advisory Committee recommends approval of Emmaus Life Sciences’s sickle cell disease drug
The Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 10 to 3 that the overall Benefit-Risk profile of Emmaus Life Sciences’s Endari for the treatment of sickle cell disease (SCD) is favorable.
May 24, 2017
UK biotech boasts Europe’s best pipeline as Brexit threat looms
Britain’s biotech sector boasts the strongest new drug pipeline in Europe but industry leaders say it needs continued access to global talent, funding and regulatory clarity to thrive in the future – all of which could be jeopardized by Brexit.